Cell Therapy in Multiple Myeloma: Evolving Treatment Considerations For Relapsed/Refractory Disease

We dived into the evolving landscape of CAR-T therapy in the treatment of multiple myeloma. In this episode, were were joined by esteemed experts Dr. Ajai Chari from UCSF, Dr. Binod Dhakal from the Medical College of Wisconsin, and Dr. Surbhi Sidana from Stanford to discuss the latest clinical insights and real-world evidence surrounding CAR-T therapy. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9... Apple Podcast: https://podcasts.apple.com/us/podcast... Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ Key topics included: • The approval and efficacy of CAR-T cilta-cel in refractory multiple myeloma settings. • Insights from clinical trials and real-world data on patient outcomes and safety profiles. • The importance of bridging therapy and disease control prior to CAR-T administration. • Updates from ASCO 2026 on the role of bridging therapy and risk stratification in patient outcomes. • The conversation around CAR-T as a consolidation strategy versus a debulking approach. • Management of acute and chronic side effects associated with CAR-T therapy, including infections and neurotoxicity. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the future of multiple myeloma treatment. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #MultipleMyeloma, #CAR_T, #ASCO2026, #BridgingTherapy, #OncologyBrothers